Needham analyst Gil Blum has maintained their neutral stance on STTK stock, giving a Hold rating today.
Gil Blum has given his Hold rating due to a combination of factors surrounding Shattuck Labs. Primarily, the company’s pipeline is still in its early stages, which limits the immediate potential for significant value creation. This is compounded by the absence of near-term catalysts that could drive the stock price upward.
Furthermore, while the company has reiterated its development timelines, including the IND filing for SL-325 expected in the third quarter of 2025 and initial clinical results anticipated in 2026, these milestones are still some time away. The focus remains on early safety data and the selection of a recommended phase 2 dose, with preclinical results showing promise but not yet translating into immediate market impact. Additionally, Shattuck’s financial position, with $61 million at the end of the first quarter of 2025, supports its operations but does not significantly alter the current outlook.